Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors

Circulation

Volumn 95, Issue 3, 1997, Pages 677-683

  Nordt, Thomas K ^a,c   Kornas, Katharina ^a   Peter, Karlheinz ^a   Fujii, Satoshi ^b   Sobel, Burton E ^b   Kübler, Wolfgang ^a   Bode, Christoph ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

atherosclerosis; coronary disease; diabetes mellitus; fibrinolysis; insulin

Indexed keywords

ANTILIPEMIC AGENT; FIBRINOGEN; GEMFIBROZIL; INSULIN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0031047343     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.3.677     Document Type: Article

References (30)

1. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
2. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
3. Tenkanen L, Mänttäri M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation. 1995;92:1779-1785.
4. Huttunen JK, Heinonen OP, Manninen V, Koskinen P, Hakulinen T, Teppo L, Mänttäri M, Frick MH. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med. 1994;235:31-39.
5. Califf RM, Fortin DF, Frid DJ, Harlan WR III, Ohman EM, Bengtson JR, Nelson CL, Tcheng JE, Mark DB, Stack RS. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol. 1991;17:2B-13B.
6. Sobel BE. Potentiation of vasculopathy by insulin: implications from an NHLBI clinical alert. Circulation. 1996;93:1613-1615.
7. Ferguson JJ. NHLBI BARI clinical alert on diabetics treated with angioplasty. Circulation. 1995;92:3371.
8. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. 1993;70:1-38.
9. Ley CJ, Swan J, Godsland IF, Walton C, Crook D, Stevenson JC. Insulin resistance, lipoproteins, body fat and hemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. J Am Coll Cardiol. 1994;23:377-383.
10. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995;91:764-770.
11. Avellone G, Di Garbo V, Panno AV, Cordova R, Lepore R, Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol. 1988;7:270-277.
12. Avellone G, Di Garbo V, Cordova R, Ranelli G, De Simone R, Bompiani G. Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia. Curr Ther Res. 1992;52:338-348.
13. Avellone G, Di Garbo V, Cordova R, Panno AV, Raneli G, De Simone R, Bompiani GD. Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis. 1993;7:416-421.
14. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost. 1990;63:174-177.
15. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60:491-494.
16. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA. 1991;88:9959-9963.
17. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost. 1989;62:723-728.
18. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89:321-330.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
20. Klassen KJ, Nordt TK, Schneider DJ, Sobel BE. Constitutive biosynthesis of plasminogen activator inhibitor type-1 (PAI-1) by cultured human aortic endothelial cells independent of insulin. Coron Artery Dis. 1993;4:713-719.
21. Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem. 1992;267:12412-12415.
22. Anfosso F, Chomiki N, Alessi MC, Vague P, Juhan-Vague I. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: metformin inhibits the stimulating effect of insulin. J Clin Invest. 1993;91:2185-2193.
23. Sirtori CR, Colli S. Influences of lipid-modifying agents on hemostasis. Cardiovasc Drugs Ther. 1993;7:817-823.
24. Charlton PA, Barnes CS, Bent FM, Bryans JS, Faint RW, Folkes AJ, Machin SJ, Mackie I, Bevan P. Evaluation of a low molecular weight inhibitor of plasminogen activator inhibitor-1. Circulation. 1995;92 (suppl I):I-486. Abstract.
25. Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia. Drugs. 1988;36:314-339.
26. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost. 1993;70:241-243.
27. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type 1. Circulation. 1992;85:1888-1893.
28. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost. 1993;70:642-647.
29. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: a potential link between lipid lowering and fibrinolysis. Circulation. 1995;92:767-772.
30. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-825.